PH12022551651A1 - METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4Ã7 INTEGRIN ANTAGONISTS - Google Patents
METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4Ã7 INTEGRIN ANTAGONISTSInfo
- Publication number
- PH12022551651A1 PH12022551651A1 PH1/2022/551651A PH12022551651A PH12022551651A1 PH 12022551651 A1 PH12022551651 A1 PH 12022551651A1 PH 12022551651 A PH12022551651 A PH 12022551651A PH 12022551651 A1 PH12022551651 A1 PH 12022551651A1
- Authority
- PH
- Philippines
- Prior art keywords
- inflammatory bowel
- methods
- bowel diseases
- antagonist
- treating inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959854P | 2020-01-10 | 2020-01-10 | |
| PCT/US2021/012842 WO2021142373A1 (en) | 2020-01-10 | 2021-01-08 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH α4β7 INTEGRIN ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022551651A1 true PH12022551651A1 (en) | 2023-11-20 |
Family
ID=76788328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/551651A PH12022551651A1 (en) | 2020-01-10 | 2021-01-08 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4Ã7 INTEGRIN ANTAGONISTS |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230063321A1 (enExample) |
| EP (1) | EP4093421A4 (enExample) |
| JP (2) | JP7744910B2 (enExample) |
| KR (1) | KR20220125268A (enExample) |
| AU (1) | AU2021205415B2 (enExample) |
| BR (1) | BR112022013628A2 (enExample) |
| CA (1) | CA3166637A1 (enExample) |
| IL (1) | IL294580A (enExample) |
| MX (1) | MX2022008486A (enExample) |
| PH (1) | PH12022551651A1 (enExample) |
| WO (1) | WO2021142373A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3104418A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| SMT202500254T1 (it) | 2020-01-15 | 2025-09-12 | Janssen Biotech Inc | Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| KR20240034224A (ko) | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 지질화된 펩티드 억제제 |
| KR20250084325A (ko) * | 2023-12-01 | 2025-06-11 | 주식회사 쓰리빅스 | 염증성 장질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013011130A (es) * | 2011-03-31 | 2013-10-30 | Genentech Inc | Metodos de administracion de antagonistas de integrina beta7. |
| WO2013078375A2 (en) * | 2011-11-23 | 2013-05-30 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
| US9273093B2 (en) * | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| CA2949215C (en) * | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| JP2017535527A (ja) * | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス， インコーポレイテッド | 新規のα４β７ペプチド単量体及び二量体拮抗薬 |
| KR20200015540A (ko) * | 2017-05-10 | 2020-02-12 | 인사이클 세라퓨틱스, 인코포레이티드 | α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드 |
-
2021
- 2021-01-08 EP EP21738981.6A patent/EP4093421A4/en active Pending
- 2021-01-08 JP JP2022542360A patent/JP7744910B2/ja active Active
- 2021-01-08 BR BR112022013628A patent/BR112022013628A2/pt not_active Application Discontinuation
- 2021-01-08 MX MX2022008486A patent/MX2022008486A/es unknown
- 2021-01-08 CA CA3166637A patent/CA3166637A1/en active Pending
- 2021-01-08 WO PCT/US2021/012842 patent/WO2021142373A1/en not_active Ceased
- 2021-01-08 PH PH1/2022/551651A patent/PH12022551651A1/en unknown
- 2021-01-08 AU AU2021205415A patent/AU2021205415B2/en active Active
- 2021-01-08 US US17/788,179 patent/US20230063321A1/en active Pending
- 2021-01-08 KR KR1020227025943A patent/KR20220125268A/ko not_active Withdrawn
-
2022
- 2022-07-07 IL IL294580A patent/IL294580A/en unknown
-
2025
- 2025-09-12 JP JP2025151922A patent/JP2025186365A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021142373A1 (en) | 2021-07-15 |
| JP2023509790A (ja) | 2023-03-09 |
| JP7744910B2 (ja) | 2025-09-26 |
| AU2021205415A8 (en) | 2023-08-10 |
| IL294580A (en) | 2022-09-01 |
| US20230063321A1 (en) | 2023-03-02 |
| AU2021205415B2 (en) | 2026-06-04 |
| KR20220125268A (ko) | 2022-09-14 |
| CA3166637A1 (en) | 2021-07-15 |
| EP4093421A1 (en) | 2022-11-30 |
| MX2022008486A (es) | 2022-10-13 |
| CN115038457A (zh) | 2022-09-09 |
| BR112022013628A2 (pt) | 2022-11-22 |
| JP2025186365A (ja) | 2025-12-23 |
| EP4093421A4 (en) | 2024-01-10 |
| AU2021205415A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021205415A8 (en) | Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists | |
| JP5646617B2 (ja) | 多発性硬化症の治療のための組成物および方法 | |
| CY1108309T1 (el) | Διαμορφωτες πυρηνικων υποδοχεων τρικυκλικων στεροειδων ορμονων | |
| EA200400982A1 (ru) | Способы лечения пациентов, страдающих от нарушения движений | |
| JPH08176100A (ja) | Ｎｍｅｐ阻害剤 | |
| MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
| NZ542866A (en) | Compositions and methods for the therapy of inflammatory bowel disease | |
| FI3672631T3 (fi) | Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| JP2020535149A5 (enExample) | ||
| EP3185881A2 (en) | Methods, agents and compositions for treatment of inflammatory conditions | |
| MX2025014083A (es) | Uso terapeutico de anticuerpos biespecificos anti proteina beta-amiloide (abeta)/receptor de transferrina (tfr) | |
| JP2020128391A (ja) | Ｎｍｄａ調節剤を使用するうつ病の治療方法 | |
| JP2004026678A (ja) | ２型糖尿病治療剤 | |
| MX2023012455A (es) | Golexanolona para usarse en el tratamiento de la fatiga o deterioro cognitivo en pacientes con enfermedad hepatica. | |
| CN105497020A (zh) | 胺类化合物的光学异构体治疗疼痛的医药用途 | |
| EP4389218A3 (en) | Composition for treating joint disease and kit containing same | |
| JP2024537284A5 (enExample) | ||
| FI3648761T3 (fi) | Telmisartaani kissan hypertension ehkäisemiseksi tai hoitamiseksi | |
| JP2020531521A5 (enExample) | ||
| Nowak et al. | Ca2+ antagonists effect an antidepressant-like adaptation of the NMDA receptor complex | |
| JP2003201238A (ja) | 脳梗塞治療用医薬組成物 | |
| TWI893157B (zh) | 具有嗎啡喃骨架之化合物或其藥理學上可容許之酸加成鹽的用途 | |
| JP2001261555A (ja) | 脳動脈中膜肥厚抑制剤 | |
| Cho et al. | Scleroderma-like manifestation in a patient with primary systemic amyloidosis: response to high-dose intravenous immunoglobulin and plasma exchange |